<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37373960</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>Promising Markers of Inflammatory and Gut Dysbiosis in Patients with Post-COVID-19 Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">971</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm13060971</ELocationID><Abstract><AbstractText>Post-COVID-19 syndrome is a complex of different symptoms, which results in a multisystemic impairment after the suffering from COVID-19 infection. The aim of the study was to reveal the clinical, laboratory, and gut disorders in patients with post-COVID-19 syndrome (<i>n</i> = 39) before and after taking part in the 14-day complex program of rehabilitation. A complete blood count, coagulation test, blood chemistry, biomarkers, and metabolites in serum samples, and gut dysbiosis were revealed in patients on the day of admission and after 14-day rehabilitation, in comparison with the variables of healthy volunteers (<i>n</i> = 48) or with reference ranges. On the day of discharge, patients noted an improvement in respiratory function, general well-being, and mood. At the same time, the levels of some metabolic (4-hydroxybenzoic, succinic, fumaric acids) and inflammatory (interleukin-6) variables, which were increased on admission, did not reach the level of healthy people during the rehabilitation program. Taxonomy disbalance was observed in patients' feces, namely, a high level of total bacterial mass, a decrease in the number of <i>Lactobacillus</i> spp., and an increase in pro-inflammatory microorganisms. The authors suggest that the post-COVID-19 rehabilitation program should be personalized, considering the patient's state together with not only the baseline levels of biomarkers, but also with the individual taxonomy of the gut microbiota.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorokina</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biochemical Technology and Nanotechnology, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya Str., 117198 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pautova</LastName><ForeName>Alisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6470-0485</Identifier><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatuev</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakharchenko</LastName><ForeName>Vladislav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onufrievich</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Federal State Budgetary Institution "N.N. Burdenko Main Military Clinical Hospital" of the Ministry of Defense of the Russian Federation, Hospital Sq., Build. 3, 105094 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grechko</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beloborodova</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2328-1610</Identifier><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chernevskaya</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9316-8907</Identifier><AffiliationInfo><Affiliation>Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 25-2 Petrovka Str., 107031 Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">4-hydroxybenzoic acid</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">fumaric acid</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">interleukin-6</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">microbial metabolites</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19</Keyword><Keyword MajorTopicYN="N">succinic acid</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37373960</ArticleId><ArticleId IdType="pmc">PMC10302977</ArticleId><ArticleId IdType="doi">10.3390/jpm13060971</ArticleId><ArticleId IdType="pii">jpm13060971</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anaya J.-M., Rojas M., Salinas M.L., Rodr&#xed;guez Y., Roa G., Lozano M., Rodr&#xed;guez-Jim&#xe9;nez M., Montoya N., Zapata E., Monsalve D.M., et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasini E., Corsetti G., Romano C., Scarabelli T.M., Chen-Scarabelli C., Saravolatz L., Dioguardi F.S. Serum Metabolic Profile in Patients with Long-COVID (PASC) Syndrome: Clinical Implications. Front. Med. 2021;8:714426. doi: 10.3389/fmed.2021.714426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.714426</ArticleId><ArticleId IdType="pmc">PMC8339407</ArticleId><ArticleId IdType="pubmed">34368201</ArticleId></ArticleIdList></Reference><Reference><Citation>Colarusso C., Maglio A., Terlizzi M., Vitale C., Molino A., Pinto A., Vatrella A., Sorrentino R. Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-&#x3b2; but Higher Levels of IL-1&#x3b1; and TGF-&#x3b2;. Biomedicines. 2021;9:1931. doi: 10.3390/biomedicines9121931.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121931</ArticleId><ArticleId IdType="pmc">PMC8698335</ArticleId><ArticleId IdType="pubmed">34944747</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Tang N., Peluso M.J., Iyer N.S., Torres L., Donatelli J.L., Munter S.E., Nixon C.C., Rutishauser R.L., Rodriguez-Barraquer I., et al. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells. 2021;10:386. doi: 10.3390/cells10020386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., das Neves P.F.M., Lima S.S., Lopes J.D.C., Torres M.K.D.S., Vallinoto I.M.V.C., Bichara C.D.A., dos Santos E.F., de Brito M.T.F.M., da Silva A.L.S., et al. Cytokine Profiles Associated with Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell. Infect. Microbiol. 2022;12:931. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J., Halim A., Halim M., Liu S., Aljeldah M., Al Shammari B.R., Alwarthan S., Alhajri M., Alawfi A., Alshengeti A., et al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers. Rev. Med. Virol. 2023;33:e2424. doi: 10.1002/rmv.2424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2424</ArticleId><ArticleId IdType="pubmed">36708022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y.-J., Liu S.-H., Manachevakul S., Lee T.-A., Kuo C.-T., Bello D. Biomarkers in long COVID-19: A systematic review. Front. Med. 2023;10:7. doi: 10.3389/fmed.2023.1085988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1085988</ArticleId><ArticleId IdType="pmc">PMC9895110</ArticleId><ArticleId IdType="pubmed">36744129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorkiewicz P., Waszkiewicz N. Biomarkers of Post-COVID Depression. J. Clin. Med. 2021;10:4142. doi: 10.3390/jcm10184142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184142</ArticleId><ArticleId IdType="pmc">PMC8470902</ArticleId><ArticleId IdType="pubmed">34575258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghini V., Meoni G., Pelagatti L., Celli T., Veneziani F., Petrucci F., Vannucchi V., Bertini L., Luchinat C., Landini G., et al. Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients. PLoS Pathog. 2022;18:e1010443. doi: 10.1371/journal.ppat.1010443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010443</ArticleId><ArticleId IdType="pmc">PMC9022834</ArticleId><ArticleId IdType="pubmed">35446921</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E., Wist J., Masuda R., Lodge S., Nitschke P., Kimhofer T., Loo R.L., Begum S., Boughton B., Yang R., et al. Incomplete Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. J. Proteome Res. 2021;20:3315&#x2013;3329. doi: 10.1021/acs.jproteome.1c00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharbi K.S., Singh Y., Hassan Almalki W., Rawat S., Afzal O., Alfawaz Altamimi A.S., Kazmi I., Al-Abbasi F.A., Alzarea S.I., Singh S.K., et al. Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre/Pro-biotics in manipulating microflora. Chem. Biol. Interact. 2022;358:109898. doi: 10.1016/j.cbi.2022.109898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2022.109898</ArticleId><ArticleId IdType="pmc">PMC8934739</ArticleId><ArticleId IdType="pubmed">35331679</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena R. Effect of Strelnikova Exercise on Respiratory Parameters among Children with LRTI In Selected Hospital Bhubaneswar. Eur. J. Mol. Clin. Med. 2020;7:1058&#x2013;1065.</Citation></Reference><Reference><Citation>Kokhan S., Vlasava S., Kolokoltsev M., Bayankin O., Kispayev T., Trofimova N., Suslina I., Romanova E. Postcovid physical rehabilitation at the sanatorium. J. Phys. Educ. Sport. 2022;22:607&#x2013;613. doi: 10.7752/jpes.2022.03076.</Citation><ArticleIdList><ArticleId IdType="doi">10.7752/jpes.2022.03076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pautova A.K., Bedova A.Y., Sarshor Y.N., Beloborodova N.V. Determination of Aromatic Microbial Metabolites in Blood Serum by Gas Chromatography&#x2013;Mass Spectrometry. J. Anal. Chem. 2018;73:160&#x2013;166. doi: 10.1134/S1061934818020089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S1061934818020089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurabov F.M., Chernevskaya E.A., Beloborodova N.V., Zurabov A.Y., Petrova M.V., Yadgarov M.Y., Popova V.M., Fatuev O.E., Zakharchenko V.E., Gurkova M.M., et al. Bacteriophage Cocktails in the Post-COVID Rehabilitation. Viruses. 2022;14:2614. doi: 10.3390/v14122614.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122614</ArticleId><ArticleId IdType="pmc">PMC9783051</ArticleId><ArticleId IdType="pubmed">36560618</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Narazaki M., Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb. Perspect. Biol. 2014;6:a016295. doi: 10.1101/cshperspect.a016295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a016295</ArticleId><ArticleId IdType="pmc">PMC4176007</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId></ArticleIdList></Reference><Reference><Citation>Erta M., Quintana A., Hidalgo J. Interleukin-6, a Major Cytokine in the Central Nervous System. Int. J. Biol. Sci. 2012;8:1254&#x2013;1266. doi: 10.7150/ijbs.4679.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.4679</ArticleId><ArticleId IdType="pmc">PMC3491449</ArticleId><ArticleId IdType="pubmed">23136554</ArticleId></ArticleIdList></Reference><Reference><Citation>Povar-Echeverr&#xed;a M., Auquilla-Clavijo P.E., Andr&#xe8;s E., Martin-S&#xe1;nchez F.J., Laguna-Calle M.V., Calvo-El&#xed;as A.E., Lorenzo-Villalba N., M&#xe9;ndez-Bail&#xf3;n M. Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study. J. Clin. Med. 2021;10:504. doi: 10.3390/jcm10030504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10030504</ArticleId><ArticleId IdType="pmc">PMC7867065</ArticleId><ArticleId IdType="pubmed">33535417</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen J.S., Maini R.N. Interleukin-6: A new therapeutic target. Arthritis Res. Ther. 2006;8:S5. doi: 10.1186/ar1969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1969</ArticleId><ArticleId IdType="pmc">PMC3226077</ArticleId><ArticleId IdType="pubmed">16899109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Lin H., Wei R.-G., Chen N., He F., Zou D.-H., Wei J.-R. Tocilizumab treatment for COVID-19 patients: A systematic review and meta-analysis. Infect. Dis. Poverty. 2021;10:71. doi: 10.1186/s40249-021-00857-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00857-w</ArticleId><ArticleId IdType="pmc">PMC8128625</ArticleId><ArticleId IdType="pubmed">34001244</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez M., Trent E., Goncalves B.D.S., Pereira D.G., Puri R., Frazier N.A., Sodhi K., Pillai S.S. Cognitive dysfunction associated with COVID-19: Prognostic role of circulating biomarkers and microRNAs. Front. Aging Neurosci. 2022;14:1164. doi: 10.3389/fnagi.2022.1020092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.1020092</ArticleId><ArticleId IdType="pmc">PMC9577202</ArticleId><ArticleId IdType="pubmed">36268187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills E., O&#x2019;neill L.A. Succinate: A metabolic signal in inflammation. Trends Cell Biol. 2014;24:313&#x2013;320. doi: 10.1016/j.tcb.2013.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2013.11.008</ArticleId><ArticleId IdType="pubmed">24361092</ArticleId></ArticleIdList></Reference><Reference><Citation>Beloborodova N., Pautova A., Sergeev A., Fedotcheva N. Serum Levels of Mitochondrial and Microbial Metabolites Reflect Mitochondrial Dysfunction in Different Stages of Sepsis. Metabolites. 2019;9:196. doi: 10.3390/metabo9100196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo9100196</ArticleId><ArticleId IdType="pmc">PMC6835733</ArticleId><ArticleId IdType="pubmed">31547099</ArticleId></ArticleIdList></Reference><Reference><Citation>Pautova A.K., Samokhin A.S., Beloborodova N.V., Revelsky A.I. Multivariate Prognostic Model for Predicting the Outcome of Critically Ill Patients Using the Aromatic Metabolites Detected by Gas Chromatography-Mass Spectrometry. Molecules. 2022;27:4784. doi: 10.3390/molecules27154784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27154784</ArticleId><ArticleId IdType="pmc">PMC9331661</ArticleId><ArticleId IdType="pubmed">35897959</ArticleId></ArticleIdList></Reference><Reference><Citation>Beloborodov N.V., Khodakova A.S., Bairamov I.T., Olenin A.Y. Microbial origin of phenylcarboxylic acids in the human body. Biochemistry. 2009;74:1350&#x2013;1355. doi: 10.1134/S0006297909120086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297909120086</ArticleId><ArticleId IdType="pubmed">19961416</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell W.R., Duncan S.H., Scobbie L., Duncan G., Cantlay L., Calder A.G., Anderson S.E., Flint H.J. Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol. Nutr. Food Res. 2013;57:523&#x2013;535. doi: 10.1002/mnfr.201200594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201200594</ArticleId><ArticleId IdType="pubmed">23349065</ArticleId></ArticleIdList></Reference><Reference><Citation>Herebian D., Seibt A., Smits S.H.J., Rodenburg R.J., Mayatepek E., Distelmaier F. 4-Hydroxybenzoic acid restores CoQ10 biosynthesis in human COQ2 deficiency. Ann. Clin. Transl. Neurol. 2017;4:902&#x2013;908. doi: 10.1002/acn3.486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.486</ArticleId><ArticleId IdType="pmc">PMC5740244</ArticleId><ArticleId IdType="pubmed">29296619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardini M., Natella F., Scaccini C., Ghiselli A. Phenolic acids from beer are absorbed and extensively metabolized in humans. J. Nutr. Biochem. 2006;17:14&#x2013;22. doi: 10.1016/j.jnutbio.2005.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2005.03.026</ArticleId><ArticleId IdType="pubmed">16242314</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto T., Nishiumi S., Fujiwara S., Yoshida M., Nishigori C. Novel serum metabolomics-based approach by gas chromatography/triple quadrupole mass spectrometry for detection of human skin cancers: Candidate biomarkers. J. Dermatol. 2017;44:1268&#x2013;1275. doi: 10.1111/1346-8138.13921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.13921</ArticleId><ArticleId IdType="pubmed">28593747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Kim S.Y., Sim G.Y., Ahn J.-H. Synthesis of 4-Hydroxybenzoic Acid Derivatives in Escherichia coli. J. Agric. Food Chem. 2020;68:9743&#x2013;9749. doi: 10.1021/acs.jafc.0c03149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.0c03149</ArticleId><ArticleId IdType="pubmed">32786833</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernevskaya E., Meglei A., Buyakova I., Kovaleva N., Gorshkov K., Zakharchenko V., Beloborodova N. Taxonomic dysbiosis of gut microbiota and serum biomarkers reflect severity of central nervous system injury. Bull. Russ. State Med. Univ. 2020;5:54&#x2013;61. doi: 10.24075/brsmu.2020.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.24075/brsmu.2020.053</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.-Y., Zhang F., Liu Q., Li A.Y., Chung A.C., Cheung C.P., Tso E.Y., Fung K.S., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., Wan Y., Chung A.C.K., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients with COVID-19 during Time of Hospitalization. Gastroenterology. 2020;159 doi: 10.1053/j.gastro.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Petakh P., Kobyliak N., Kamyshnyi A. Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method. Front. Cell. Infect. Microbiol. 2023;13:108. doi: 10.3389/fcimb.2023.1142578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1142578</ArticleId><ArticleId IdType="pmc">PMC9947359</ArticleId><ArticleId IdType="pubmed">36844398</ArticleId></ArticleIdList></Reference><Reference><Citation>Righi E., Lambertenghi L., Gorska A., Sciammarella C., Ivaldi F., Mirandola M., Sartor A., Tacconelli E. Impact of COVID-19 and Antibiotic Treatments on Gut Microbiome: A Role for Enterococcus spp. Biomedicines. 2022;10:2786. doi: 10.3390/biomedicines10112786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10112786</ArticleId><ArticleId IdType="pmc">PMC9687172</ArticleId><ArticleId IdType="pubmed">36359311</ArticleId></ArticleIdList></Reference><Reference><Citation>Abed J., Maalouf N., Manson A.L., Earl A.M., Parhi L., Emg&#xe5;rd J.E.M., Klutstein M., Tayeb S., Almogy G., Atlan K.A., et al. Colon Cancer-Associated Fusobacterium nucleatum May Originate from the Oral Cavity and Reach Colon Tumors via the Circulatory System. Front. Cell. Infect. Microbiol. 2020;10:400. doi: 10.3389/fcimb.2020.00400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00400</ArticleId><ArticleId IdType="pmc">PMC7426652</ArticleId><ArticleId IdType="pubmed">32850497</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss J., Kaplan G.G., Beck P.L., Rioux K., Panaccione R., DeVinney R., Lynch T., Allen-Vercoe E. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 2011;17:1971&#x2013;1978. doi: 10.1002/ibd.21606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.21606</ArticleId><ArticleId IdType="pubmed">21830275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff L., Martiny D., Deyi V.Y.M., Maillart E., Clevenbergh P., Dauby N. COVID-19&#x2013;Associated Fusobacterium nucleatum Bacteremia, Belgium. Emerg. Infect. Dis. 2021;27:975&#x2013;977. doi: 10.3201/eid2703.202284.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2703.202284</ArticleId><ArticleId IdType="pmc">PMC7920680</ArticleId><ArticleId IdType="pubmed">33292922</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar D., Mohanty A. Gut microbiota and COVID-19-possible link and implications. Virus Res. 2020;285:198018. doi: 10.1016/j.virusres.2020.198018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198018</ArticleId><ArticleId IdType="pmc">PMC7217790</ArticleId><ArticleId IdType="pubmed">32430279</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;oniewski I., Skonieczna-&#x17b;ydecka K., So&#x142;ek-Pastuszka J., Marlicz W. Probiotics in the Management of Mental and Gastrointestinal Post-COVID Symptomes. J. Clin. Med. 2022;11:5155. doi: 10.3390/jcm11175155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11175155</ArticleId><ArticleId IdType="pmc">PMC9457065</ArticleId><ArticleId IdType="pubmed">36079082</ArticleId></ArticleIdList></Reference><Reference><Citation>Beloborodova N.V., Grechko A.V., Gurkova M.M., Zurabov A.Y., Zurabov F.M., Kuzovlev A.N., Megley A.Y., Petrova M.V., Popova V.M., Redkin I.V., et al. Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study) Gen. Reanimatol. 2021;17:4&#x2013;14. doi: 10.15360/1813-9779-2021-6-4-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.15360/1813-9779-2021-6-4-14</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ettorre G., Ceccarelli G., Marazzato M., Campagna G., Pinacchio C., Alessandri F., Ruberto F., Rossi G., Celani L., Scagnolari C., et al. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front. Med. 2020;7:389. doi: 10.3389/fmed.2020.00389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00389</ArticleId><ArticleId IdType="pmc">PMC7358304</ArticleId><ArticleId IdType="pubmed">32733907</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky J.P., Govindarajulu U., Bagiella E., Goswami R., Kale M., Campbell K.N., Meliambro K., Chen Z., Aberg J.A., Lin J.J. Association of Vaccination with the Persistence of Post-COVID Symptoms. J. Gen. Intern. Med. 2022;37:1748&#x2013;1753. doi: 10.1007/s11606-022-07465-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07465-w</ArticleId><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., De Martino M., Palese A., Gerussi V., Bontempo G., Graziano E., Visintini E., D&#x2019;Elia D., Dellai F., Marrella F., et al. Post&#x2013;COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin. Microbiol. Infect. 2022;28:1140&#x2013;1148. doi: 10.1016/j.cmi.2022.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC8940723</ArticleId><ArticleId IdType="pubmed">35339673</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund O., Eviatar T., Bornstein G. Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: A case series and literature review. Rheumatol. Int. 2022;42:905&#x2013;912. doi: 10.1007/s00296-022-05106-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05106-3</ArticleId><ArticleId IdType="pmc">PMC8915139</ArticleId><ArticleId IdType="pubmed">35275269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>